TWSTTwist Bioscience Corp
Biological Products, (no Diagnostic Substances)
- Revenue
- $377M
- 20% YoY
- Operating margin
- -36.2%
- 49% YoY
- EBITDA
- −$111M
- 41% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$113M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired17% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear12% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $132M | $204M | $245M | $313M | $377M | 20% |
| Operating income | −$153M | −$235M | −$217M | −$221M | −$136M | 38% |
| Net income | −$152M | −$218M | −$205M | −$209M | −$78M | 63% |
| Operating cash flow | −$112M | −$124M | −$142M | −$64M | −$48M | 26% |
| Capex | $27M | $102M | $28M | $5M | $28M | 452% |
| Stock-based comp | $37M | $80M | $30M | $51M | $64M | 27% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $79M · 49
- Net
- −$79M
Pay vs performance
No pay-versus-performance disclosure yet.